机构：[1]Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China[2]Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado 80045, USA[3]Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing 210000, China[4]Department of Isotopic Laboratory of Nanjing Medical University, Nanjing 210000, China[5]HLA Laboratory of Jiangsu Province People’s Hospital, Nanjing 210029, China[6]Department of Endocrinology and Metabolism, Nanjing General Hospital of Nanjing Military Command, Nanjing 210002, China[7]Department of Endocrinology and Metabolism, Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China[8]Department of Endocrinology and Metabolism, Zhongda Hospital Southeast University, Nanjing 210009, China[9]Department of Endocrinology and Metabolism, Nanjing First Hospital, Nanjing 210000, China[10]Department of Endocrinology and Metabolism, Nanjing Children’s Hospital, Nanjing 210008, China[11]Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210011, China[12]Department of Endocrinology and Metabolism, Nanjing Governmental Hospital, Nanjing 210008, China[13]Department of Endocrinology and Metabolism, Northern Jiangsu People's Hospital, Yangzhou 225001, China[14]Department of Endocrinology and Metabolism, Wuxi People’s Hospital, Wuxi 214023, China[15]Department of Endocrinology and Metabolism, Jiangsu Jiangyin People’s Hospital, Wuxi 214400, China[16]Department of Endocrinology and Metabolism, The Affiliated Hospital of Xuzhou Medical College, Xuzhou 221006, China[17]Department of Endocrinology and Metabolism, Xuzhou Central Hospital, Xuzhou 221009, China[18]Department of Endocrinology and Metabolism, The First Affiliated Hospital of Soochow University, Suzhou 215006, China[19]Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China[20]Department of Endocrinology and Metabolism, The First People’s Hospital of Kunshan, Suzhou 215300, China[21]Department of Endocrinology and Metabolism, Huai’an Second People’s Hospital, Huai’an 223002, China[22]Department of Endocrinology and Metabolism, Huai’an First People’s Hospital, Huai’an 223300, China[23]Department of Endocrinology and Metabolism, The First People’s Hospital of Zhenjiang, Zhenjiang 212002, China[24]Department of Endocrinology and Metabolism, Yancheng City No.1 People’s Hospital, Yancheng 224005, China[25]Department of Endocrinology and Metabolism, Jiangsu Taizhou People’s Hospital, Taizhou 225300, China[26]Department of Endocrinology and Metabolism, The First People’s Hospital of Nantong, Nantong 226000, China[27]Department of Endocrinology and Metabolism, Affiliated Hospital of Nantong University, Nantong 226001, China[28]Department of Endocrinology and Metabolism, Changzhou No. 2 People’s Hospital, Changzhou 213003, China[29]Department of Endocrinology and Metabolism, The First People’s Hospital of Lianyungang, Lianyungang 222002, China[30]Department of Endocrinology and Metabolism, Binhai People’s Hospital of Yancheng City, Yancheng 224500, China[31]Department of Endocrinology and Metabolism, Xuzhou Tumor Hospital, Xuzhou 221005, China[32]Department of Endocrinology and Metabolism, Tianjin Medical University Metabolic Disease Hospital, Tianjin 300070, China[33]Department of Endocrinology and Metabolism, Wuhu No.2 People’s Hospital, Wuhu 241000, China[34]Center for Biotechnology and Genomic Medicine, Medical College of Georgia, GA Regents University, Augusta 30912, USA
Type 1 diabetes mellitus is heterogeneous in many facets. The patients suffered from type 1 diabetes present several levels of islet function as well as variable number and type of islet-specific autoantibodies. This study was to investigate prevalence and heterogeneity of the islet autoantibodies and clinical phenotypes of type 1 diabetes mellitus; and also discussed the process of islet failure and its risk factors in Chinese type 1 diabetic patients. A total of 1,291 type 1 diabetic patients were enrolled in this study. Demographic information was collected. Laboratory tests including mixed-meal tolerance test, human leukocyte antigen alleles, hemoglobinA1c, lipids, thyroid function and islet autoantibodies were conducted. The frequency of islet-specific autoantibody in newly diagnosed T1DM patients (duration shorter than half year) was 73% in East China. According to binary logistic regressions, autoantibody positivity, longer duration and lower Body Mass Index were the risk factors of islet failure. As the disease developed, autoantibodies against glutamic acid decarboxylase declined as well as the other two autoantibodies against zinc transporter 8 and islet antigen 2. The decrease of autoantibodies was positively correlated with aggressive beta cell destruction. Autoantibodies can facilitate the identification of classic T1DM from other subtypes and predict the progression of islet failure. As there were obvious heterogeneity in autoantibodies and clinical manifestation in different phenotypes of the disease, we should take more factors into consideration when identifying type 1 diabetes mellitus.
基金：
This work was supported by the National
Natural Science Foundation of China (81270897, 81300668, 81370939,
81400813, 81400808, 81530026, 81370922), the Jiangsu Provincial Special
Program of Medical Science (BL2012026) and the Project Funded by
the Priority Academic Program Development of Jiangsu Higher Education
Institutions support this study.
第一作者机构：[1]Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Endocrinology and Metabolism, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China[3]Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing 210000, China
推荐引用方式(GB/T 7714)：
Jin Liu,Lingling Bian,Li Ji,et al.The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients[J].SCIENCE CHINA-LIFE SCIENCES.2016,59(9):930-9.doi:10.1007/s11427-016-5052-3.
APA：
Jin Liu,Lingling Bian,Li Ji,Yang Chen,Heng Chen...&Tao Yang.(2016).The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients.SCIENCE CHINA-LIFE SCIENCES,59,(9)
MLA：
Jin Liu,et al."The heterogeneity of islet autoantibodies and the progression of islet failure in type 1 diabetic patients".SCIENCE CHINA-LIFE SCIENCES 59..9(2016):930-9
